Current approaches of nanomedicines in the market and various stage of clinical translation
Reads0
Chats0
TLDR
In this paper , the authors provide a snapshot of nanomedicines that have been currently launched or in the clinical trials, which manifests a diversified trend in carrier types, applied indications and mechanisms of action.About:
This article is published in Acta Pharmaceutica Sinica B.The article was published on 2022-03-01 and is currently open access. It has received 60 citations till now. The article focuses on the topics: Medicine & Medicine.read more
Citations
More filters
Journal ArticleDOI
Artificial Intelligence Aids in Development of Nanomedicines for Cancer Management.
TL;DR: In this article , the advances in AI-enabled nanomedicines in cancer management are elaborated and their application in diagnosis, monitoring and therapy as well as in precision medicine development is discussed.
Journal ArticleDOI
Bioengineered nanogels for cancer immunotherapy.
TL;DR: Recent advances of nanogel-based immunotherapy to deliver immunomodulatory small molecule drugs, antibodies, genes and cytokines, to target antigen presenting cells, form cancer vaccines, and enable chimeric antigen receptor (CAR)-T cell therapy are mainly summarized.
Journal ArticleDOI
Fabrication of active targeting lipid nanoparticles: Challenges and perspectives
TL;DR: In this paper , a review on the techniques to fabricate active targeting lipid nanoparticles is presented, with a focus on the one-pot assembly and post-insertion functionalization.
Journal ArticleDOI
Melanoma Management: From Epidemiology to Treatment and Latest Advances
TL;DR: An updated overview of various aspects related to cutaneous melanoma, from epidemiology, etiology, clinical presentation, prevention, diagnosis and staging, as well as the latest advances in clinical trials regarding new drugs and/or combinations, including nanotechnology-based strategies are reviewed.
Journal ArticleDOI
Promising Nanocarriers to Enhance Solubility and Bioavailability of Cannabidiol for a Plethora of Therapeutic Opportunities
TL;DR: Almost all the developed nanoparticles have simple architectures, are well-known and safe nanocarriers, or are even simple nanosuspensions, and are very promising for a plethora of therapeutic opportunities because of the versatility of the release, the crossing of physiological barriers, and the number of possible routes of administration.
References
More filters
Journal ArticleDOI
Cancer nanomedicine: progress, challenges and opportunities.
TL;DR: Novel engineering approaches are discussed that capitalize on the growing understanding of tumour biology and nano–bio interactions to develop more effective nanotherapeutics for cancer patients.
Journal ArticleDOI
Doxil®--the first FDA-approved nano-drug: lessons learned.
TL;DR: This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use and demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles.
Journal ArticleDOI
mRNA vaccines — a new era in vaccinology
TL;DR: A detailed overview of mRNA vaccines is provided and future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use are considered.
Journal ArticleDOI
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more
TL;DR: Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Journal ArticleDOI
Albumin-based nanoparticles as potential controlled release drug delivery systems.
TL;DR: The current review embodies an in-depth discussion of albumin nanoparticles with respect to types, formulation aspects, major outcomes of in vitro and in vivo investigations as well as site-specific drug targeting using various ligands modifying the surface of albumins with special insights to the field of oncology.
Related Papers (5)
CLINICAL TRIALS FOR SEVERE SEPSIS: Past Failures, and Future Hopes
Steven M. Opal,Alan S. Cross +1 more